Background and Objectives: Wound infiltration with available local anesthetics generally provides analgesia for less than 8 hrs. The site 1 sodium-channel toxin neosaxitoxin (neoSTX) produced analgesia for over 24 hrs in animals and human volunteers. In this randomized, double-blind trial, we examined the postoperative course of patients undergoing laparoscopic cholecystectomy under a standardized general anesthesia with wound infiltration using either neoSTX or bupivacaine. We hypothesized that neoSTX would reduce pain compared with bupivacaine at 12 hrs postoperatively.
Methods: Patients received preincisional infiltration of laparoscope entry sites with 20 mL containing either neoSTX (total dose, 100 μg) or bupivacaine 0.25% (total dose, 50 mg). The primary outcome measure was the visual analog pain score at 12 hrs postoperatively. Secondary outcomes included repeated pain scores at rest and with movement, analgesic use, functional recovery, and adverse effects. Groups were compared using Mann-Whitney U tests for pain scores, Fisher exact test for proportions of patients with severe pain and complete analgesia, and Kaplan-Meier curves for time to full recovery.
Results: Among 137 subjects, 69 were randomized to neoSTX and 68 to bupivacaine. Median pain scores at rest and with movement 12 hrs postoperatively were lower in the neoSTX group compared with the bupivacaine group (P < 0.01). Additional pain measures and recovery parameters also favored neoSTX. No serious adverse events occurred, and no adverse events were more frequent in the neoSTX group.
Conclusions: NeoSTX shows promise as a long-acting local anesthetic. Future studies will examine dose response, combination formulations, and safety with dose escalation.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This study was supported by FONDECYT grant 11080242.
Dr. A. J. Rodríguez-Navarro is the Chief Medical Officer of Proteus SA, and in case of commercial development, he might receive equity. Dr. Berde and coworkers at Children's Hospital Boston hold a US patent on site 1 sodium-channel toxins as prolonged-duration local anesthetics. Children's Hospital Boston is currently under discussions with Proteus SA regarding joint commercial development. In the event of such joint development, Dr. Berde, his coworkers, and Children's Hospital Boston could receive royalty payments. Drs. Berde and Zurakowski were not involved in the experimentation, but became involved during the writing and statistical analysis phases of the manuscript.